Seal Rock Therapeutics’ Out-Licensing Agreement with GENFIT

Wilson Sonsini Goodrich & Rosati advised Seal Rock on the transaction.Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, has announced…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Leila Ahmed

This content is for Standard 1 Year members only.
Login Join Now